Particular features of lipid metabolism in psoriasis patients with concomitant metabolic syndrome

Cover Page


Cite item

Full Text

Abstract

Goal. To assess particular features of lipid metabolism in psoriasis patients with concomitant metabolic syndrome (MS). Materials and methods. Total cholesterol, triglycerides (TG) and high density lipoprotein cholesterol (HDL cholesterol) were determined in the blood serum of psoriasis patients by the enzymatic method using a spectrophotometer at the wavelength of 500 nm. The level of low-density lipoprotein cholesterol (LDL cholesterol) was determined by the calculation method using W. Friedewald’s formula (1972). The cholesterol atherogenicity ratio (CAR) was calculated by the formula: CAR = (Total cholesterol - HDL cholesterol) / HDL cholesterol Results. Patients suffering from psoriasis vulgaris are distinguished by lipid metabolism abnormalities characterized by the development of atherogenic dyslipidemia, increase in the total cholesterol, TG and LDL cholesterol in blood, reduction in the HDL cholesterol level and increased CAR. Patients with concomitant metabolic disorders have more obvious changes.

About the authors

A. G. Pashinyan

The Russian National Research Medical University named after N.I. Pirogov

Author for correspondence.
Email: noemail@neicon.ru
Россия

YE. V. Dontsova

Voronezh State Medical Academy of a Name of N.N. Burdenko of Ministry of Health of Russia

Email: ledn89@mail.ru
Россия

References

  1. Langley R., Krueger G., Griffiths C. Psoriasis: epidemiology, clinical features and quality of life. Ann. Rheum. Dis. 2005; 64 (Suppl II): 18-23.
  2. Cowen P. Management of psoriasis. Aust. Fam. Physician. 2001; 30 (11): 1033-1037.
  3. Kubanova A.A., Kubanov A.A., Melekhina L.E. et al. Results of the analysis of dermatovenerologic healthcare organizations activity in the Russian Federation for 2012. Vestn dermatol venerol 2013; 5: 21-39. [Кубанова А.А., Кубанов А.А., Мелехина Л.Е. и др. Результаты анализа деятельности медицинских организаций дерматовенерологического профиля в Российской Федерации за 2012 год. Вестн дерматол венерол 2013; (5): 21-39.]
  4. Pashinyan A.G., Heydar S.A., Arutyunyan G.B., Dzhavayeva D.G. Psoriasis: etiology, pathogenesis, clinical manifestations. Vestn. esthetic medicine. 2014; 13 (1): 79-85. [Пашинян А.Г., Хейдар С.А., Арутюнян Г.Б., Джаваева Д.Г. Псориаз: этиология, патогенез, клинические проявления. Вестн эстетич мед 2014; 13 (1): 79-85.]
  5. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin. Exp. Dermatol. 2001; 26 (4): 314-320.
  6. Yakubovich A. I. Correction of violations of a lipidic exchange at patients with psoriasis. Russian Journal of Skin and Sexually Transmitted Diseases. 2011; 6: 29-32. [Якубович А.И. Коррекция нарушений липидного обмена у больных псориазом. Росс журн кож и вен бол 2011; (6): 29-32.]
  7. Butov Yu.S.,Vasenova V.Yu.,Shmakova A.S. etc. Clinical and biochemistry status at patients with psoriasis and methods of its correction. Russian Journal of Skin and Sexually Transmitted Diseases. 2009; 5: 23-27. [Бутов Ю.С., Васенова В.Ю., Шмакова А.С. и др. Клиникобиохимический статус у больных псориазом и методы его коррекции. Росс журн кожн и вен бол 2009; (5): 23-27.]
  8. Akcali C., Buyukcelik B., Kirtak N. et al. Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. J. Int. Med. Res. 2014; 42(2): 386-394.
  9. Ma C., Harskamp C.T., Armstrong E.J., Armstrong A.W. The association between psoriasis and dyslipidaemia: a systematic review. Br. J. Dermatol. 2013; 168 (3): 486-495.
  10. Mamedov M.N. Manual on diagnostics and treatment of a metabolic syndrome. M.: Multiprint. 2005. [Мамедов М.Н. Руководство по диагностике и лечению метаболического синдрома. М.: Мультипринт. 2005.]
  11. Al-Mutairi N., Al-Farag S., Al-Mutairi A. et al. Comorbidities associated with psoriasis: an experience from the Middle East. J. Dermatol. 2010; 37: 146-155.
  12. Christophers E. Comorbidities in psoriasis. Clin. Dermatol. 2007; 25 (6): 529-534.
  13. Chazova I.E., Mychka V.B. Metabolic syndrome. M, 2004. 60-70. [Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004. 60-70.]
  14. Kim C.R., Lee J. H. An observational study on the obesity and metabolic status of psoriasis patients. Ann. Dermatol. 2013; 25 (4): 440-444.
  15. Azfar R., Gelfand J. Psoriasis and metabolic disease: epidemiology and pathophysiology.Curr. Opin. Rheumatol. 2008; 20 (4): 416-422.
  16. Gisondi P., Girolomoni G. Psoriasis and athero-thrombotic diseases: disease-specific and nondisease-specific risk factors. Semin. Thromb. Hemost. 2009; 35: 313-324.
  17. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287 (3): 356-359.
  18. Jensen P., Thyssen J.P., Zachariae C. et al. Cardiovascular risk factors in subjects with psoriasis: a cross-sectional general population study. Int. J. Dermatol. 2013; 52 (6): 681-683.
  19. Solomon G. The role of weight loss in the treatment of psoriasis: evidence that psoriasis is a systemic inflammatory disorder linked to metabolic syndrome. Br. J. Dermatol. 2014; 170 (3): 492-493.
  20. Farshchian M., Ansar A., Sobhan M.R. Psoriasis and risk factors of metabolic syndrome: A case-control study. Dermatology & Cosmetic. 2013; 4 (1): 10-18.
  21. Papp K., Poulin Y., Vieira A. Examining the risk of cardiovascular disease in patients with psoriasis: a critical review. J. Cutan. Med. Surg. 2013; 17 (2): 89-105.
  22. Grozdev I., Kast D., Cao L.et al. Physical and mental impact of psoriasis severity as measured by the compact Short Form-12 Health Survey (SF-12) quality of life tool. J. Invest. Dermatol. 2012; 132: 1111-1116.
  23. Eckel R.H., Grundy S.M., Zimmet P.Z. The metabolic syndrome. Lancet. 2005; 365: 1415-1428.
  24. Gelfand J.M., Dommasch E.D., Shin D.B. et al. The risk of stroke in patients with psoriasis. J. Invest. Dermatol. 2009; 129: 2411-2418.
  25. Recommendations of experts of the All-Russian scientific organization of cardiologists about diagnostics and treatment of a metabolic syndrome: second revision. M., 2009. 28 p. [Рекомендации экспертов Всероссийского научного общества кардиологов по диагностике и лечению метаболического синдрома: второй пересмотр. М., 2009. 28 с.]
  26. Komisarenko I.A. Metabolic syndrome as a polimorbidity problem. Consiliummedicum. Cardiology. 2012; 14 (1): 13-17. [Комисаренко И.А. Метаболический синдром как проблема полиморбидности. Consilium medicum. Кардиология. 2012; 14 (1): 13-17.]
  27. Sigurdardottir G., Ekman A.K., Stahle M. et al. Systemic treatment and narrowband ultraviolet B differentially affect cardiovascular risk markers inpsoriasis J Am Acad Dermatol 2014; 19.
  28. Mikryukov A.V. Features of a course of psoriasis at patients with the excess body weight and obesity. Clinical dermatol. andvener. 2013; 6: 52-56. [Микрюков А.В. Особенности течения псориаза у больных с избыточной массой тела и ожирением. Клин дерматол и венерол 2013; (6): 52-56.]

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2014 Pashinyan A.G., Dontsova Y.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies